All the news Showing 10 of 61 articles from: Disease course and symptomsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Statins reduce risk of progression to cirrhosis in people with HIV/HCV co-infection Michael Carter / 30 August 2016 Treatment with statins decreases the risk of progression to liver cirrhosis in people with HIV/hepatitis C virus (HCV) co-infection, investigators from the United States report in AIDS. The protective effect of statins was ... Many people in the US with chronic hepatitis B not being properly monitored Michael Carter / 26 August 2016 Many people with chronic hepatitis B (CHB) virus infection have infrequent medical monitoring, according to US research published in the online edition of Clinical Infectious Diseases. Analysis of the records of over 2000 ... Cardiovascular disease risk is higher for people with hepatitis C Keith Alcorn / 20 January 2016 People with hepatitis C are at higher risk of dying from cardiovascular disease, suffering a stroke or developing cardiovascular problems than people with similar risk factors for heart disease who ... Liver cancer risk will remain elevated for people with cirrhosis cured of hepatitis C Keith Alcorn / 16 November 2015 The burden of liver cancer and cirrhosis caused by hepatitis C is likely to continue to grow in the United States despite curative treatment for hepatitis C, and people who have cirrhosis ... Hepatitis B patients on long-term entecavir or tenofovir have low mortality, but liver cancer remains a risk Liz Highleyman / 03 June 2015 More than 95% of people with chronic hepatitis B were still alive after five years on antiviral therapy with entecavir (Baraclude) or tenofovir (Viread) and most deaths were due to non-liver-related causes, according ... Statin use associated with lower risk of liver decompensation and death in hepatitis C patients with cirrhosis Liz Highleyman / 19 May 2015 People with hepatitis and liver cirrhosis were significantly less likely to progress to decompensated disease and less likely to die if they used statins to control blood cholesterol, according to an analysis of ... Sofosbuvir, daclatasvir and ribavirin cures hepatitis C for most people with advanced cirrhosis or liver transplants Liz Highleyman / 29 April 2015 An interferon-free regimen of sofosbuvir, daclatasvir and ribavirin for 12 weeks produced sustained response rates of 83% for people with hepatitis C virus (HCV) who had advanced liver cirrhosis and 94% for ... Alcohol misuse the strongest predictor of severe liver damage and death in French people with hepatitis C Keith Alcorn / 28 April 2015 People with hepatitis C have a much greater risk of liver-related hospitalisation or death if they have an alcohol use disorder or another serious co-morbidity such as HIV infection, chronic kidney disease ... Deferring hepatitis C treatment can lead to liver cancer and death, despite cure Liz Highleyman / 05 March 2015 People with HIV and hepatitis C co-infection who delay hepatitis C treatment remain at risk for liver failure, hepatocellular carcinoma and liver-related death even after being cured – with outcomes worsening the ... Sofosbuvir/ledipasvir with ribavirin is highly effective for people with decompensated cirrhosis Liz Highleyman / 12 November 2014 An oral regimen of sofosbuvir/ledipasvir plus ribavirin taken for 12 weeks cured most hepatitis C patients with decompensated cirrhosis, the most advanced stage of liver disease, according to a presentation ... ← Prev1...34567Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Transmission and prevention Diagnosis and monitoring Disease course and symptoms Treatment HIV and HBV HCV and HBV Hepatitis delta Living with HBV Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive